Charles River Laboratories International (NYSE:CRL) Updates FY 2025 Earnings Guidance

Charles River Laboratories International (NYSE:CRL) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 9.100-9.600 for the period, compared to the consensus earnings per share estimate of 9.600. The company issued revenue guidance of $3.8 billion-$3.9 billion, compared to the consensus revenue estimate of $3.9 billion. Charles River Laboratories International also updated its FY25 guidance to $9.10-$9.60 EPS.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on CRL. TD Cowen boosted their target price on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research note on Monday, November 11th. UBS Group reaffirmed a “neutral” rating and set a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. StockNews.com lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. William Blair lowered Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Finally, Robert W. Baird dropped their target price on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a report on Thursday. Three investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $196.43.

Charles River Laboratories International Stock Performance

Shares of Charles River Laboratories International stock opened at $167.59 on Thursday. Charles River Laboratories International has a one year low of $150.79 and a one year high of $275.00. The company has a market cap of $8.57 billion, a price-to-earnings ratio of 20.99, a PEG ratio of 6.01 and a beta of 1.37. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The business’s 50 day moving average price is $174.02 and its 200 day moving average price is $188.99.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.16. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The firm’s quarterly revenue was down 1.1% compared to the same quarter last year. During the same quarter last year, the firm earned $2.46 earnings per share. On average, research analysts predict that Charles River Laboratories International will post 10.16 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).